Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects
Visceral leishmaniasis (VL) is a vector-borne chronic infectious disease caused by the protozoan parasite Leishmania donovani or Leishmania infantum. VL is a serious public health problem, causing high morbidity and mortality in the developing world with an estimated 0.2 -0.4 million new cases each...
Main Authors: | Om Prakash eSingh, Shyam eSundar |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00296/full |
Similar Items
-
Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis
by: Pradyot Bhattacharya, et al.
Published: (2013-02-01) -
Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis
by: Pradyot Bhattacharya, et al.
Published: (2013-04-01) -
IL-10 and TGF-β Induced Arginase Expression Contributes to Deficient Nitric Oxide Response in Human Visceral Leishmaniasis
by: Manu Kupani, et al.
Published: (2021-02-01) -
Immunobiology of visceral leishmaniasis
by: Susanne eNylén, et al.
Published: (2012-08-01) -
Immunotherapy for Visceral Leishmaniasis: Ability of Factors Produced during Anti-leishmania Responses of Skin Test Positive Adults to Inhibit Peripheral Blood Mononuclear Cell Activities Associated with Visceral Leishmaniasis
by: Holaday Bettie J
Published: (1999-01-01)